Global Strategy for the Diagnosis, Management and Prevention of COPD: 2003 update

Fabbri, Leonardo; Hurd, Suzanne S.

doi:10.1183/09031936.03.00063703

Cited by 554 publications

(289 citation statements)

References 3 publications

Supporting

Mentioning

273

Contrasting

Unclassified

Order By: Relevance

“…These patients were not excluded from the sample because, for COPD epidemiological studies, the international criterion for a diagnosis of COPD is a postbronchodilator FEV 1 /FVC ratio lower than 0.7 (9,10,14). The adoption of this criterion definitely involves the risk of including asthmatics or normal aged people.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Chronic obstructive pulmonary disease is underdiagnosed and undertreated in São Paulo (Brazil): results of the PLATINO study

Nascimento

Camelier

Rosa

et al. 2007

Braz J Med Biol Res

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

“…COPD diagnosis was based on a postbronchodilator FEV 1 /FVC ratio lower than 0.7 and COPD stage was determined using the most recent version of the GOLD guidelines (14).…”

Section: Diagnosis Of Chronic Obstructive Pulmonary Diseasementioning

confidence: 99%

Chronic obstructive pulmonary disease is underdiagnosed and undertreated in São Paulo (Brazil): results of the PLATINO study

Nascimento

Camelier

Rosa

et al. 2007

Braz J Med Biol Res

View full text Add to dashboard Cite

“…In contrast with other leading chronic diseases, its prevalence and disease-related morbidity and mortality are increasing (2)(3)(4)(5)(6). Bronchodilators are typically prescribed for maintenance therapy of the reversible obstructive component of the disease.…”

Section: Introductionmentioning

confidence: 99%

Bronchodilating effect of combined therapy with ipratropium bromide and ondansetron in patients with COPD

Pauwels

Joos

Fogarty

et al. 2008

Pulmonary Pharmacology & Therapeutics

View full text Add to dashboard Cite

The objectives of this study were to determine the effect of single and repeat dosing with oral ondansetron, a 5-HT3-specific receptor blocker, on the degree and duration of bronchodilation induced by inhaled ipratropium bromide in patients with COPD. Five clinics and university medical centers in four countries participated in the study; forty seven patients with COPD were randomized to treatment; 44 completed all treatments. Patients had a baseline (pre-bronchodilator) FEV1 > 1 liter and post-bronchodilator (200 mcg salbutamol) FEV1 < 90% of predicted, with FEV1 reversibility (to 80 mcg inhaled ipratropium bromide and 400 mcg salbutamol) of at least 12% or 200 ml over baseline. The study was divided into two parts. In Part A, each patient received in a random order, four-way cross-over manner, single doses of ondansetron placebo (oral) plus ipratropium bromide placebo (inhaled), ondansetron placebo plus ipratropium bromide 40 mcg inhaled via MDI, ondansetron 24 mg oral plus ipratropium bromide placebo and ondansetron 24 mg plus ipratropium bromide 40 mcg. In Part B, each patient received in a random order, two-way crossover manner, ipratropium bromide 40 mcg tid via MDI plus ondansetron 8 mg oral, qid, for two days; on day 3 patients received a single dose of ipratropium bromide 40 mcg plus 8 mg oral ondansetron. Alternatively, patients received ipratropium bromide via MDI and oral ondansetron placebo, as described above. Statistically significant differences in weighted mean FEV1 (0-6 hours), peak FEV1 and FEV1 determined 6 hours post-dose were noted comparing ipratropium bromide to placebo. Similar positive results were observed for sGaw and FVC. Addition of ondansetron to ipratropium bromide did not significantly modify values obtained with ipratropium alone. Ipratropium bromide induced a marked bronchodilation, compared to placebo. Addition of ondansetron (single or repeated doses) did not significanlty increase the degree or duration of A c c e p t e d m a n u s c r i p t 2 bronchodilation induced by ipratropium alone. sGaw was consistently more sensitive than FEV1 in measuring extent and duration of bronchodilation.

show abstract

“…Each subject was personally interviewed face-to-face by trained interviewers who collected the patient's demographic data as well as information related to risk factors such as tobacco smoking. The recruitment and the clinical analyses were conducted at the Department of Respiratory Medicine in West China Hospital of Sichuan University; clinical analyses were performed according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria [22] . COPD patients were enrolled when they suffered from cough, sputum production and dyspnea at least upon exertion and showed chronic irreversible airflow limitation defined by an FEV 1 (forced expiratory volume in 1 s) to FVC (forced vital capacity) ratio <70%, and FEV 1 predicted <80% after the inhalation of a β 2 -agonist.…”

Section: Subjectsmentioning

confidence: 99%

Association between fibroblast growth factor 7 and the risk of chronic obstructive pulmonary disease

Kuang

Liu

et al. 2012

Acta Pharmacol Sin

View full text Add to dashboard Cite

Aim: Fibroblast growth factor 7 (FGF7) is involved in a number of physiological and pathological processes, including lung disease. However, relatively little is known about the effect of FGF7 gene polymorphisms on chronic obstructive pulmonary disease (COPD) susceptibility. This study aimed to investigate the association between FGF7 polymorphisms with COPD susceptibility in a Chinese Han population. Methods: We conducted a case-control study of 279 COPD patients and 367 age-and gender-distribution-matched control subjects. The tagging SNPs rs10519225 and rs7170426 in FGF7 were genotyped by SNaPshot. The associations of each SNP genotype and haplotype constructed by these loci with COPD were analyzed. Results: A multivariate analysis showed that rs10519225 was significantly associated with an increased risk of COPD (P=0.011, OR=1.535, FDR q=0.022), whereas no association was found for rs7170426. Linkage disequilibrium (LD) analysis showed that these loci were in weak LD, with an r 2 of 0.033 and a D′ of 0.232 (95% CI: 0.150-0.520). The haplotype constructed by allele G at rs10519225 and allele A at rs7170426 was associated with a decreased susceptibility to COPD (P=0.012, OR=0.751, FDR q=0.048). Conclusion: These findings suggest that FGF7 may be one susceptibility factor for COPD.

show abstract

Global Strategy for the Diagnosis, Management and Prevention of COPD: 2003 update

Cited by 554 publications

References 3 publications

Chronic obstructive pulmonary disease is underdiagnosed and undertreated in São Paulo (Brazil): results of the PLATINO study

Chronic obstructive pulmonary disease is underdiagnosed and undertreated in São Paulo (Brazil): results of the PLATINO study

Bronchodilating effect of combined therapy with ipratropium bromide and ondansetron in patients with COPD

Association between fibroblast growth factor 7 and the risk of chronic obstructive pulmonary disease

Contact Info

Product

Resources

About